Browse by author
Lookup NU author(s): Professor Alan Calvert
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Fifty-two patients with progressive advanced breast cancer were treated with the novel antifolate CB 3717 (N10-propargyl-5,8-dideazofolic acid) which inhibits thymidylate synthetase. Forty-six patients were pretreated with hormones, 43 with cytotoxic chemotherapy and 39 patients with both treatments. Eight of 48 patients (16.6%) evaluable for response had partial responses (confidence limits 7.4–30.2%, 95% confidence level) following CB 3717 administration. Liver function abnormalities, reversible in most cases, were the commonest toxicities and were frequently accompanied by malaise. Severe renal failure occurred in eight patients, five of whom had had partial responses to CB 3717. This study shows the importance of thymidylate synthetase as a target for therapy but the clinical value of CB 3717 is limited by its hepatic and renal toxicities.
Author(s): Cantwell, B. M. J., MaCaulay, V., Harris, A. L., Kaye, S. B., Smith, I. E., Milsted, R. A. V., Calvert, A. H.
Publication type: Article
Publication status: Published
Journal: European Journal of Cancer and Clinical Oncology
Year: 1988
Volume: 24
Issue: 4
Pages: 733-736
Print publication date: 01/04/1988
ISSN (print): 0277-5379
ISSN (electronic): 1879-0852
URL: http://dx.doi.org/10.1016/0277-5379(88)90307-0
DOI: 10.1016/0277-5379(88)90307-0
Altmetrics provided by Altmetric
